Valneva (NASDAQ:VALN) Price Target Lowered to $18.00 at HC Wainwright

Valneva (NASDAQ:VALN) had its target price decreased by HC Wainwright from $19.00 to $18.00 in a research report report published on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the stock.

Valneva Stock Performance

NASDAQ VALN opened at $4.74 on Thursday. Valneva has a 52 week low of $3.62 and a 52 week high of $9.50. The firm has a 50 day moving average of $4.28 and a two-hundred day moving average of $5.80. The company has a current ratio of 2.78, a quick ratio of 2.25 and a debt-to-equity ratio of 0.70.

Institutional Trading of Valneva

A hedge fund recently raised its stake in Valneva stock. AlphaCentric Advisors LLC grew its holdings in Valneva SE (NASDAQ:VALN) by 33.7% during the third quarter, according to the company in its most recent filing with the SEC. The fund owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the quarter. AlphaCentric Advisors LLC owned about 0.15% of Valneva worth $717,000 at the end of the most recent reporting period. 11.39% of the stock is owned by institutional investors.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.